close
This ad will auto close in 10 seconds
Sun Pharma to acquire oncology product from Novartis for $175 million

Sun Pharma to acquire oncology product from Novartis for $175 million

Drug major Sun Pharmaceutical Industries on Thursday said it it will acquire a branded oncology product, Odomzo, from Novartis for an upfront payment of USD 175 million.

Sniff your way to `slimmer` you with `love hormone` spray

Results in 10 overweight and obese men suggest that one way oxytocin lowers food intake might be by improving self-control, said co-investigator Franziska Plessow of the Massachusetts General Hospital, Boston.

NeoBiocon to sell anti-diabetic drug in UAE

Vildagliptin is available as monotherapy and in combination with metformin. Both the drugs commands over 30 percent of the DPP-IV market in the UAE.

Antim Baazi: NeoBiocon Partners with Novartis

NeoBiocon Partners with Novartis which shows good momentum in Biocon intra-day trading.

US fines Novartis $390 million over pharmacy kickbacks

Novartis admitted that it gave specialty pharmacies exceptional rebates and patient referrals in exchange for recommending Exjade.

Novartis India gets FIPB nod to sell OTC biz to GSK CPL

The Foreign Investment Promotion Board (FIPB) has approved the proposal made by GSK CPL to acquire the company's OTC division, Novartis India said in a BSE filing.

New-look GSK bets on consumer health spending

GSK predicted on Wednesday its consumer health sales would grow at a mid-single-digit compound annual rate over the next five years, slightly ahead of overall company sales.

Novartis warns of currency drag on 2015 earnings

Swiss drugmaker Novartis on Thursday posted declining sales in the first quarter and cautioned that dollar strength may be a bigger-than-expected drag on full-year figures.

GSK Pharma to transfer cancer drug portfolio to Novartis arm

GlaxoSmithKline Pharmaceuticals board on Thursday approved transfer of its cancer drugs portfolio to an arm of Novartis in India in return for acquiring vaccines portfolio as part of a global deal between the two-multinational pharma giants struck last year.

Novartis Q3 net loss at Rs 1.18 crore

Drug firm Novartis India Ltd on Wednesday reported a net loss of Rs 1.18 crore for the third quarter ended December 31, 2014.

EU puts conditions on deals involving Novartis, GSK

The European Union on Wednesday approved mega deals involving drugmakers Novartis of Switzerland and GlaxoSmithKline of Britain, provided they sell off assets in the vaccines and consumer health businesses.

Novartis profits jump 12% on new drug sales

Novartis profits jump 12% on new drug sales

Swiss pharmaceuticals giant Novartis said Tuesday strong sales of new products helped push its net profit up 12 percent last year despite harsh competition from cheaper copycat generic drugs.

HC order 'disappointing', says Cipla

Drug maker Cipla Friday expressed disappointment over the Delhi High Court order that restrained the company from manufacturing and selling any medicine containing 'Indacaterol', saying that the interim verdict would deny patients access to drugs they need.

Novartis shares up nearly 2% at close

Surrendering most of early gains in-line with a weak stock market, shares of Novartis India ended nearly 2 percent higher Wednesday, a day after fair trade regulator CCI approved a multi-billion dollar deal between global pharma giants GlaxoSmithKline Plc and Novartis.

CCI clears multi-billion Novartis-GSK pharma deal

Fair trade regulator CCI has approved a multi-billion dollar deal between global pharma giants GlaxoSmithKline Plc and Novartis, as it did not find the transaction to be anti-competitive ion India.

HC reserves order on Novartis-Cipla drug dispute

The Delhi High Court has reserved its verdict on a dispute between pharma firms Novartis and Cipla over manufacturing of the drug Indacaterol, used for treatment of chronic obstructive pulmonary disease.

Cipla-Novartis patent row: DIPP looking into merit of case

The Commerce and Industry Ministry is looking into the merit of Cipla's demand for revocation of patents of Swiss drug major Novartis for respiratory drug Indacaterol citing the need for public health access.

NPPA slaps Rs 300-crore penalty on Novartis for overcharging

Drug major Novartis has been slapped with a Rs 300-crore penalty by drug regulator NPPA for overcharging consumers on sale of Voveran, its best-selling painkiller medicine.

GSKCH picks Zubair Ahmed for global role in JV with Novartis

The company said it would make a separate announcement of the organisational structure under Ahmed.

EU clears Novartis plan to sell animal health to Eli Lilly

EU regulators cleared on Friday the proposed sale of the animal health business of Swiss pharmaceutical giant Novartis to US group Eli Lilly, saying it would not violate competition rules.